21 CFR 212.20
What activities must I perform to ensure drug quality?
- Inspections citing it: 101
- Of those classified, ended OAI: 16%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 212.20(e)
- 53 · Written QA procedures established, followed
- 212.20(d)
- 34 · Determination need for investigation
- 212.20(c)
- 8 · Specifications and processes
- 212.20(a)
- 6 · Oversight of production operations
Regulation Text
eCFR, as of Nov 6, 2026(a) Production operations. You must oversee production operations to ensure that each PET drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, that it is supposed to have.
(b) Materials. You must examine and approve or reject components, containers, closures, in-process materials, packaging materials, labeling, and finished dosage forms to ensure compliance with procedures and specifications affecting the identity, strength, quality, or purity of a PET drug.
(c) Specifications and processes. You must approve or reject, before implementation, any initial specifications, methods, processes, or procedures, and any proposed changes to existing specifications, methods, processes, or procedures, to ensure that they maintain the identity, strength, quality, and purity of a PET drug. You must demonstrate that any change does not adversely affect the identity, strength, quality, or purity of any PET drug.
(d) Production records. You must review production records to determine whether errors have occurred. If errors have occurred, or a production batch or any component of the batch fails to meet any of its specifications, you must determine the need for an investigation, conduct investigations when necessary, and take appropriate corrective actions.
(e) Quality assurance. You must establish and follow written quality assurance procedures.
Recently Cited Sites
Newest inspections citing this section; each opens the site- Pharmalogic Puerto Rico IncUnited States · Aug 21, 2026
- Pharmalogic New York City, LLCUnited States · Aug 19, 2026
- Mayo Clinic PET Radiochemistry FacilityUnited States · Jul 31, 2026
- Northland Nuclear Medicine, LLCUnited States · May 29, 2026
- PETNET Solutions, Inc.United States · Mar 24, 2026
- Jubilant DraxImage RadiopharmaciesUnited States · Mar 23, 2026
- Biomedical Research Foundation of Northwest LouisianaUnited States · Feb 20, 2026
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR